Awani International
  • LIVE
  • Videos
  • US-China
  • BRICS-RT
  • ASEAN
  • West Asia
  • Shows
  • Podcast
  • BM
    EN
  • LIVE
  • Login
  • BM
    EN
  • LIVE
  • Login
Awani International
  • LIVE
  • Videos
  • US-China
  • BRICS-RT
  • ASEAN
  • West Asia
  • Shows
  • Podcast
Russia's Lavrov sees no 'bright future' for economic ties with US
China critic Jimmy Lai sentenced to 20 years in jail after landmark Hong Kong trial
Agreements on oil, computer chips will help smooth the way for US-India trade deal, says minister
  • PRIVACY POLICY
  • TERMS OF USE
  • ADVERTISE WITH US
  • INVESTOR

Astro AWANI | Copyright © 2025 Measat Broadcast Network Systems Sdn Bhd 199201008561 (240064-A)

Merck says study shows COVID-19 drug causes quick reduction in virus

Reuters
Reuters
06/03/2021
06:59 MYT
Merck says study shows COVID-19 drug causes quick reduction in virus
The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS pic
BENGALURU: U.S. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19.
"The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising," said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies.
The antiviral is being currently tested in a Phase 2/3 trial that is set to be completed in May.
Merck decided to focus on therapeutics after its two COVID-19 vaccines failed to generate desired immune responses, prompting it to abandon the program in January.
Related Topics
#COVID-19
#merck
#drug
#study
Must-Watch Video
Stay updated with our news